13 results on '"Spelman, Lynda"'
Search Results
2. Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
3. Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis
4. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials
5. Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
6. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
7. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
8. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
9. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
10. Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
11. Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2
12. Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp, or Approximately 250 cm2 on the Chest: A Phase III, Randomized, Controlled Trial
13. Ingenol Mebutate 0.06% Gel for Field Treatment of Actinic Keratosis on 250 cm2 of Skin on Trunk and Extremities: A Randomized Dose-Finding Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.